美国的生物技术创业者可以申请韩国的一项计划,协助他们进入亚洲市场。 U.S. biotech startups can apply for a South Korea program aiding their entry into the Asian market.

首尔生物枢纽和细胞室启动了2025年首尔生物枢纽-银河系全球开放创新方案,以帮助美国生物技术和医疗创业企业进入亚洲市场。 Seoul Bio Hub and Celltrion have launched the 2025 Seoul Bio Hub-Celltrion Global Open Innovation program to help U.S. biotech and medical startups enter the Asian market. 该倡议针对最近七年内建立的初创企业,支持抗体、、小分子以及细胞和基因疗法方面的公司。 Targeting startups established within the last seven years, the initiative supports companies in antibodies, peptides, small molecules, and cell and gene therapies. 将利用韩国强大的临床基础设施、研究环境和日益增长的生物技术市场,预计到2030年将达816亿美元。 Selected firms will receive customized assistance and collaboration opportunities to expand globally, leveraging South Korea’s strong clinical infrastructure, research environment, and growing biotech market, projected to reach $81.6 billion by 2030. 申请截止日期为 2025年9月30日 The application deadline is September 30, 2025.